Page 24 - Astrazeneca

AstraZeneca coronavirus vaccine trial in US on hold until midweek: Report

AstraZeneca on Saturday said it had restarted its trial in Britain after regulators completed their review of a serious side effect in one trial participant there

Not enough Covid-19 vaccines for everybody till 2024 end: Adar Poonawalla

Poonawalla estimates that the world will need 15 billion doses of the vaccine if it is taken in two steps

AstraZeneca-Oxford's coronavirus vaccine trials resume in Brazil

AstraZeneca paused global trials temporarily last week after an unexplained illness in a participant in Britain.

AstraZeneca resumes Oxford Covid vaccine trial after UK green signal

The late-stage trials of the experimental vaccine, one of the most advanced in development, were suspended this week after an illness in a study subject in Britain

DCGI aks Serum Institute to suspend recruitment for Oxford vaccine trials

DCGI has directed Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate

Top headlines: AstraZeneca still aiming for vaccine; MGNREGS fund drying up

From India awaiting drug regulator's nod to restart the vaccine trial to drying up MGNREGA funds, here are top headlines this morning

AstraZeneca still aiming for Oxford Covid-19 vaccine by year-end, says CEO

Soriot sought to reassure investors after the company and its partner confirmed earlier this week that they had temporarily stopped giving people the experimental shot

Covid-19: Indian sites await DCGI nod to restart Oxford vaccine trial

The Drug Controller General of India (DCGI) V G Somani will take a call after he receives data from the Data and Safety Monitoring Board (DSMB) in the UK as well as India

AstraZeneca's pause on Covid-19 vaccine trial a 'wake-up call', says WHO

"This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared," Soumya Swaminathan told a virtual briefing from Geneva

Covid-19: Serum Institute puts Oxford vaccine's India trials on hold

Serum Institute of India (SII) on Thursday said it is pausing clinical trials of AstraZeneca Oxford COVID-19 vaccine candidate in the country. Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study. However, SII on Wednesday said it was continuing with the trials and had not faced any issues. SII's latest announcement also comes against the backdrop of the central drug regulator DCGI issuing a show-cause notice to SII for not informing it about AstraZeneca pausing the clinical trials of the Oxford vaccine candidate in other countries. "We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials," SII said in a statement. The Pune-based vaccine maker also said it is following instructions of the Drugs Controller General of India (DCGI), it added. In the show-cause notice, DCGI V G Somani had asked SII as to why the permission granted for conducting phase 2 and 3 clinical trial

Serum Institute puts India trials of AstraZeneca's Covid-19 vaccine on hold

Serum Institute of India has put trials of AstraZeneca's Covid-19 vaccine candidate on hold until the British drugmaker restarts the trials, Serum said

India's single-day spike, Trump downplaying virus, FB's anti-vaxxer posts

On Wednesday, Maharashtra and Delhi recorded their highest single-day spike of 23,816 and 4,039 cases, respectively

Covid-19: Serum Institute to halt trial of Oxford vaccine after DCGI notice

On Tuesday, AstraZeneca had decided to stop trials after a participant fell sick with an unexplained illness.

DCGI issues notice to Serum Institute over Oxford's Covid trial suspension

The DGCI sought an immediate reply saying else "it shall be construed that you have no explanation to offer and action deemed fit will be taken against you"

Fauci says Astrazeneca vaccine pause unfortunate but a safety valve

Anthony Fauci said that AstraZeneca's decision to pause global trials of its coronavirus vaccine was unfortunate but not an uncommon safety precaution in a vaccine development process

AstraZeneca Pharma shares dip over 3% after it halts Covid vaccine trials

Shares of AstraZeneca Pharma, closed over 3 per cent lower on Wednesday after its Covid-19 vaccine study was paused following a participant's unexplained illness

MARKET WRAP: Sensex slips 171 pts amid weak global cues; RIL up over 2.5%

All that happened in the markets today.

Covid: India leads world in daily tally; resumes more metro lines today

According to the health ministry, Maharashtra, Andhra Pradesh, Karnataka, Uttar Pradesh and Tamil Nadu account for 62% of total active coronavirus cases in the country

US, European Covid-19 vaccine developers pledge to uphold testing rigour

The promise to play by established rules underlines a highly politicised debate over what action is needed to rein in Covid-19 quickly and to jumpstart global business and trade

AstraZeneca Pharma tanks 13% as parent firm halts Covid-19 vaccine trials

The company, which is formulating and testing the vaccine in collaboration with Oxford University, is among the front-runners for last-stage trials of potential virus vaccine